Research programme: fibrotic disease therapeutics - Bristol-Myers Squibb/California Institute for Biomedical Research
Latest Information Update: 07 Jan 2015
At a glance
- Originator California Institute for Biomedical Research
- Developer Bristol-Myers Squibb; California Institute for Biomedical Research
- Class Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Fibrosis
Most Recent Events
- 05 Jan 2015 Preclinical trials in Fibrosis in USA (unspecified route)